<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: A <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> is often associated with an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> in cerebrovascular disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, in <z:e sem="disease" ids="C0270786" disease_type="Disease or Syndrome" abbrv="">Binswanger disease</z:e> (BD), no information is available on the coagulation-fibrinolysis pathway except for the presence of high plasma fibrinogen levels </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To determine the association of BD and coagulation-fibrinolysis pathway activation </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: We examined the levels of fibrinogen, thrombin-antithrombin complex, prothrombin fragment(1+2), and cross-linked D-dimer in 17 patients with BD, 24 neurologic patients without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, and 26 patients with <z:e sem="disease" ids="C0333559" disease_type="Disease or Syndrome" abbrv="">lacunar infarction</z:e> in either the <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> stage </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: As compared with the non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and <z:e sem="disease" ids="C0333559" disease_type="Disease or Syndrome" abbrv="">lacunar infarction</z:e> groups, the patients with BD had significantly elevated levels of thrombin-antithrombin complex (P&lt;.001), prothrombin fragment(1+2) (P&lt;.05), and cross-linked D-dimer (P&lt;.01) </plain></SENT>
<SENT sid="5" pm="."><plain>There was also a significant increase in fibrinogen levels compared with the non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> group (P&lt;.05) </plain></SENT>
<SENT sid="6" pm="."><plain>In the BD group, 8 patients in stable condition (ie, those without obvious neurologic deficits in the past 3 months) showed <z:mpath ids='MPATH_458'>normal</z:mpath> levels or a mild increase in their fibrinogen, thrombin-antithrombin complex, prothrombin fragment(1+2), or cross-linked D-dimer levels </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, 9 patients with BD with a <z:hpo ids='HP_0011011'>subacute</z:hpo> aggravation of their focal or subcortical cerebral functions (deteriorating group) showed a significant increase in their thrombin-antithrombin complex levels compared with the stable patients (P&lt;.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Similarly, the fibrinogen, prothrombin fragment(1+2), and cross-linked D-dimer levels were elevated in the deteriorating patients, but this trend did not reach statistical significance </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These results indicate that the coagulation-fibrinolysis pathway is activated in patients with BD with a <z:hpo ids='HP_0011011'>subacute</z:hpo> aggravation </plain></SENT>
<SENT sid="10" pm="."><plain>Coagulation activation may result in the formation of microthrombi and microcirculatory disturbances in the brains of these patients, and thus promote further biological and neurologic insults </plain></SENT>
</text></document>